specializes in mergers and acquisitions (M&A) advisory services and invests in selective businesses with potential for high growth. The Company has designed a three-pronged business model that can potentially yield long term rewards with relatively diversified revenue streams, by
Acquiring and consolidating undervalued opportunities in selective high-growth industries to create value for our shareholders and target partners by combining expertise in both the product and capital markets.
Acting as an incubator for emerging companies whose production and operational capability can be brought up to speed relatively quickly if product acceptance occurs.
Taking minority interest in client-partner companies to align with their long-term interest and help build enduring value for our investors.
can take a client from start up into their future. ICBS will work with each client to insure their project will be a success. ICBS
has the expertise and contacts that allow them to bring clients ideas into play. The following are just some of the services they offer:
- BUSINESS CONSULTING
- INVESTMENT BANKING
- BUSINESS PLANS
- ACQUISITIONS & MERGERS
- TURNAROUND & RESTRUCTURING
- INTERNATIONAL CORPORATE PLACEMENT IN NORTH AMERICA
- IMMIGRATION VISAS & PROGRAMS
- GOVERNMENTS GRANTS
- RESEARCH & DEVELOPMENT TAX CREDITS
- ACCOUNTING SYSTEMS
- BOOKKEEPING SERVICES
- AUDITING SERVICES
- I.P.O’s PUBLIC OFFERING IN THE U.S.
- REVERSE MERGERS
ICBS Companies , Partnerships & Interests
Canadian Bio Med
Canadian Bio Med Systems
is an ophthalmology company that is engaged in the development of pharmaceutical agents for two of the most important disease states in that market. Glaucoma and Age related macular degeneration.
Canadian Bio Med Systems
along with its partner Ocular Therapeuticsowns the exclusive worldwide licensing rights to two patented or patent pending drugs in the field of ophthalmology.It is believed that these drugs have the potential to revolutionize the way Glaucoma and Age Related Macular Degeneration (AMD) are treated.
Glaucoma is a leading cause of blindness in the United States and the world.The current treatment for Glaucoma consists of eye drops usually used one, two or more times each day.Usually more than one drug is prescribed.Due to the frequency of applications required, the largest problem is with patient compliance.The drug under development by CBMS at the University of Arizona has the remarkable prospect of needing to be used only once or twice per year by the patient. The market for Glaucoma treatment is huge.It is projected that by 2010 there will be 60.5 million people with the most common form of Glaucoma. Novartis alone sells over $1.5 billion of Glaucoma medications annually. AMD is the leading cause of blindness worldwide, for people over 55 years of age.There is currently no cure for the disease.
Several large companies are working with product development drugs which are still experimental and extremely expensive.The drug under development by CBMS has the benefits of requiring fewer treatments then current drugs, and will be far less expensive.
There is extensive intellectual property with U.S .and world patents issued and pending.
Ramapo Valley Brewery
Ramapo Valley Brewery New York
was established in Hillburn New York in 2000. The company was the result of a small micro brewery that first started brewing in 1997.
Their unique brewing process and Recipes, along with the use of the valley spring waters, resulted in award winning beers. Over the next three years , the demand for their beers grew at such an astounding rate that the founders, decided to make the transition to a formal brewery, and Ramapo Valley Brewery was born.
RVB is the only Kosher certified brewery in the United States , and certified to produce Kosher for Passover beer.
R.V.B brews some of the worlds most exciting beers including the award winning gluten free Honey Beer
and the dynamic Skull Crusher
with 10% alcohol.’
Ramapo Razz Ale
October Fest Lager
Suffern Station Porter
Indian Pale Ale
ICBS holds a 50% interest iTrend has developed a market investment Artificial Intelligence system that assists investors.
is an Artificial Intelligent investment system which can help investors build portfolios, develop strategies, manage cash and control risks.
The development of our software was primarily an innovation spin-off from a Canadian university project. Our development team included students and developers supervised by a professor which worked on the project for over 3 years. Today, the research using genetic algorithm to manage funds continue and the lead designer is working as a trader in US and Hong Kong stocks.
Most people invest by experience: learning from one’s own successful or failed investment decisions in the past. There are several drawbacks of such style of investment:
Selective memory: people intend to remember what they are willing to remember.
Not knowing the boundaries: experience in a bull market may not be suitable in a bear market any more.
Statistical noise: the sample people observing is often too small to develop general rules
prevents emotional interference.
works with historical complex financial market, analysis and non-quantitative data to build your own investment database.
continues to accumulate data on stocks minute by minute , assimilate, investigate and calculate this information to enable
to project the performance of your stock.
Bio Spec Global Solutions
ICBS Ltd. has acquired twenty- five percent interest in BioSpec Global Solutions Inc., who has developed
state-of-the-art technologies for rapid, onsite (remote) monitoring of microbial contamination in drinking water, recreational water, agriculture & food production, pharmaceuticals and medical applications.
The TOGS 9000 is a bio-photonic incubation/detection instrument which quantifies microbial contamination. The analysis results can be obtained directly on-site through a computer or can be directly connected and controlled by an appropriate laboratory and or regulatory authority in a secure monitoring system using ‘AGACSSTM’(TM) software and the internet. As an example, The EPA could literally monitor all drinking water sources down to the individual well owner and do it quickly, accurately and cost effectively. Or the Center for Infectious Diseases ( CID ) could monitor the spread of antibiotic resistant microbes (ARMs) across the U.S. at the patient level. Doctors could determine the effectiveness of an antibiotic in their office for their patients before prescribing the antibiotic rather than the try and hope method presently used. The healthcare system could save hundreds of millions of dollars and hospital/doctor liabilities reduced. This technology is revolutionary for a global market.
BIOSPEC believes the progression of this technology is leading towards wireless data transmission. Connecting the AQUASURE 9000 to a cell phone like device for data transmission to a laboratory much the same way pictures are sent by a cell phone will be cost effective, allowing the technology to penetrate the huge consumer market which presently isn’t addressed.
BIOSPEC technology is recognized as the method for the detecting of microbial contamination. By entering in to a series of license agreements with well positioned companies
(industry leaders), intellectual property protected, and its varied applications and global use realized.
George Tsoukas, Chairman
Garth McIntosh, President, CEO, CFO